progression-free survival

progression-free survival

,

PFS

In cancer care, the time during which a patient shows no signs or symptoms of the growth or the spreading of a tumor.
References in periodicals archive ?
United States-based Merck's Keytruda (pembrolizumab) in combination with pemetrexed (Alimta) plus platinum chemotherapy has improved overall survival and progression-free survival of a certain type of lung cancer patients in a phase three trial, it was reported yesterday.
KEYNOTE-189 showed significant improvement in overall survival and progression-free survival for patients receiving KEYTRUDA in the first-line setting in combination with traditional chemotherapy, compared with those receiving chemotherapy alone," said Dr.
These data from the pivotal trial in sALCL demonstrate the long-term clinical benefit of ADCETRIS in the treatment of this disease, with an estimated five-year survival rate of 60 percent and progression-free survival rate of 39 percent, said Jonathan Drachman, M.
Median progression-free survival was only 4 months, and the 1-year progression-free survival rate was only 35%.
After treatment, the median progression-free survival time was seven weeks for the chemotherapy group, but this more than doubled to 15.
A preplanned interim analysis was performed by an independent data and safety monitoring committee after 359 progression-free survival events were observed.
Both trials were powered to detect an improvement in progression-free survival, not overall survival.
ORLANDO - Neoadjuvant chemotherapy with interval debulking surgery yields similar overall and longer progression-free survival when compared with primary debulking surgery for women with stage IV epithelial ovarian cancer, according to a retrospective study.
Arecent study found that the response and progression-free survival rates of patients with newly diagnosed metastatic non-small cell lung cancer (NSCLC) who had received gefitinib was significantly higher than patients who had received carboplatin plus paclitacel (73.
This is the first controlled trial to demonstrate an improvement in median progression-free survival using the prostate cancer working group-2-defined radiological criteria, coordinating investigator Prof.
In a study sponsored by lapatinib manufacturer GlaxoSmithKline, progression-free survival was more than twofold higher among the women who were treated with the all-oral combination of these two agents, compared with those who received letrozole alone, according to the statement issued by the FDA.